A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma

PHASE3RecruitingINTERVENTIONAL
Enrollment

194

Participants

Timeline

Start Date

September 18, 2021

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2025

Conditions
Advanced Neuroendocrine Carcinoma
Interventions
DRUG

Surufatinib plus Toripalimab

Surufatinib is a tablet in the form of 50mg, oral, once a day; Toripalimab is an injection in the form of 240mg, intravenous, once three weeks.

DRUG

5-fluorouracil, Calcium folinate and Irinotecan

Irinotecan 180 mg/m\^2, Calcium folinate 400 mg/m\^2, 5-FU total 2800 mg/m\^2 will be administrated once two weeks.

Trial Locations (1)

100142

RECRUITING

Beijing Cancer Hospital, Beijing

All Listed Sponsors
lead

Hutchison Medipharma Limited

INDUSTRY